A Phase 3 interventional study of Ezetimibe 10 mg and Rosuvastatin 2.5 mg in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 28th largest by enrollment of the 97 interventional ones that give a count, is one of 4 that started in 2016, is one of 50 in phase 3, and was the 75th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
Punjab Institute of Cardology · Sites in Pakistan
Ages 18+
By country, each count listing its studies:
Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 148 across the 97 interventional studies. Of the 91 that completed or were terminated, 47 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 98 have an industry lead sponsor. The 10 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
91 studies in Hypercholesterolemia by Organon & Co.: none open now, none under way, none of them phase 3. Of 91 finished, 43 (47%) have results posted.
Among the 91 studies in Hypercholesterolemia by Organon & Co., this one is the 41st largest by enrollment of the 81 interventional ones that give a count, is one of 2 that started in 2016, is one of 58 in phase 3, and was the 83rd registered.
Organon & Co.’s Hypercholesterolemia studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 98 studies testing ezetimibe in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 91 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety and tolerability of 2 dose levels of MK-0653H in Japanese participants. The primary hypotheses are that the administration of MK-0653H is safe and tolerable and that MK-0653H is superior to single entity of Ezetimibe and Rosuvastatin in percent reduction from baseline in low-density lipoprotein-cholesterol (LDL-C) after 12 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
Drug: Ezetimibe 10 mg · Drug: Placebo for Rosuvastatin
1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
Drug: Rosuvastatin 2.5 mg · Drug: Placebo for Ezetimibe · Drug: Placebo for Rosuvastatin
2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
Drug: Rosuvastatin 2.5 mg · Drug: Placebo for Ezetimibe
1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
Drug: Ezetimibe 10 mg · Drug: Rosuvastatin 2.5 mg · Drug: Placebo for Rosuvastatin
1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
Drug: Ezetimibe 10 mg · Drug: Rosuvastatin 2.5 mg
Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)
Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated. Results were reported as a M-estimate.
Time frame: Baseline and Week 12
Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized
Time frame: up to 14 weeks
Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event
An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that had study drug discontinued due to an AE was summarized.
Time frame: up to 12 weeks
Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs
Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.
Time frame: up to 14 weeks
Percentage of Participants Who Experience 1 or More Gallbladder-related AEs
Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.
Time frame: up to 14 weeks
Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs
Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.
Time frame: up to 14 weeks
Percentage of Participants Who Experience 1 or More Hepatitis-related AEs
Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.
Time frame: up to 14 weeks
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)
Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L..
Time frame: up to 12 weeks
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)
Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)
Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 5x ULN or greater were recorded. The AST ULN was 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)
Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 10x ULN or greater were recorded. The AST ULN was 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.
Time frame: up to 12 weeks
Percentage of Participants With Potential Hy's Law Condition
Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations \>3xULN, with serum alkalinephosphatase \<2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN
Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms
Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.
Time frame: up to 12 weeks
Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms
Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.
Time frame: up to 12 weeks
| Milestone | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Started | 35 | 72 | 71 | 71 | 72 |
| Completed | 35 | 71 | 71 | 67 | 70 |
| Not completed | 0 | 1 | 0 | 4 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
Participants had LDL-C levels assessed at baseline and after 12 weeks of study drug administration. The change from baseline was calculated. Results were reported as a M-estimate.
| Percentage Change | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C) | -18.7 (-21.9 to -15.5) | -39.8 (-42.0 to -37.5) | -47.2 (-49.4 to -44.9) | -54.6 (-56.9 to -52.3) | -60.5 (-62.8 to -58.2) |
An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that reported at least 1 AE was summarized
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience at Least 1 Adverse Event (AE) | 31.4 | 34.7 | 42.3 | 40.8 | 37.5 |
An AE was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. The percentage of participants that had study drug discontinued due to an AE was summarized.
| Percentage of participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event | 0.0 | 0.0 | 0.0 | 2.8 | 1.4 |
Gastrointestinal-related AEs included all preferred terms within system organ class of Gastrointestinal Disorders except Chapped Lips and Toothache.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs | 0.0 | 6.9 | 4.2 | 8.5 | 2.8 |
Gallbladder-related AEs included Bile Duct Obstruction, Bile Duct Stone, Bile Duct Stenosis, Biliary Colic, Cholangitis, Cholecystectomy, Cholecystitis, Cholelithiasis, Gallbladder Disorder, Gallbladder Perforation, Hepatic Pain, and Hydrocholecystis.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience 1 or More Gallbladder-related AEs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Allergic Reaction or Rash AEs included Allergy to Arthropod Sting, Anaphylactoid Reaction, Anaphylactic Reaction, Anaphylatic Shock, Anaphylactoid Shock, Angioedema, Conjunctivitis Allergic, Contrast Media Reaction, Dermatitis, Dermatitis Allergic, Dermatitis Atopic, Dermatitis Bullous, Dermatitis Contact, Dermatitis Psoriasiform, Drug Hypersensitivity, Eczema, Eosinophila, Erythema, Eye Allergy, Face Oedema, Hypersensitivity, Mechanical Urticaria, Palmar Erythema, Periorbital Oedema, Photodermatosis, Photosensitivity Allergic reaction, Photosensitivity Reaction, Pigmentation Disorder, Pruritus, Pruritus Generalised, Rash, Rash Erythematous, Rash Follicular, Rash Generalised, Rash Maculo-Papular, Rash Papulosquamous, Rash Pruritic, Rash Pustular, Rash Vesicular, Rhinitis, Rhinitis Allergic, Rosacea, Skin Exfoliation, Skin Disorder, Skin Hyperpigmentation, Skin Lesion, Skin Mass, Skin Ulcer, Subcutaneous Nodule, Swelling Face, Systemic Lupus Erythematosus Rash, Urticaria.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs | 0.0 | 1.4 | 4.2 | 2.8 | 2.8 |
Hepatitis-related AEs included Cholestasis, Cytolytic Hepatitis, Hepatic Cyst, Hepatic Failure, Hepatic Lesion, Hepatic Necrosis, Hepatitis, Hepatitis Cholestatic, Hepatitis Fulminant, Hepatitis Infectious, Hepatocellular Injury, Hepatomegaly, Jaundice, Jaundice Cholestatic.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience 1 or More Hepatitis-related AEs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT that were 3 x ULN or greater were recorded. The ALT ULN was 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 |
Participants had AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of AST that were 3 x ULN or greater were recorded. The AST ULN was 40 U/L..
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 3 x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 |
Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 5x ULN or greater were recorded. The ALT ULN was 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 5x ULN or greater were recorded. The AST ULN was 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had ALT levels assessed throughout the 12 week treatment period. Participants who had an assessments of ALT that was 10x ULN or greater were recorded. The ALT ULN was 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had AST levels assessed throughout the 12 week treatment period. Participants who had an assessments of AST that was 10x ULN or greater were recorded. The AST ULN was 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had ALT and AST levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of ALT and/or AST that were 10x ULN or greater were recorded. The ALT and AST ULNs were 40 U/L.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Percentage of Participants with Potential Hy's Law Condition (defined as serum ALT or serum AST elevations \>3xULN, with serum alkalinephosphatase \<2xULN and total bilirubin (TBL) ≥2xULN) was summarized. The ALT and AST ULNs were 40 U/L. The ULN for alkaline phosphatase was 359 IU/L and the ULN for total bilirubin was 1.2 mg/dL.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants With Potential Hy's Law Condition | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had creatine phosphokinase (CK) levels assessed throughout the 12 week treatment period. Participants who had any CK level that was ≥10 x ULN were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Participants had CK levels assessed throughout the 52 week treatment period. Participants who had any CK level that was ≥10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly-related to study drug were recorded. The CK ULNs for males and females were 287 IU/L and 163 IU/L, respectively.
| Percentage of Participants | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Collected over up to 2 weeks post last dose of study drug (up to 14 weeks total). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ezetimibe 10 mg | 0/35 (0%) | 0/35 (0%) | 6/35 (17.1%) |
| Rosuvastatin 2.5 mg | 0/72 (0%) | 0/72 (0%) | 8/72 (11.1%) |
| Rosuvastatin 5.0 mg | 0/71 (0%) | 1/71 (1.4%) | 11/71 (15.5%) |
| Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | 0/71 (0%) | 0/71 (0%) | 6/71 (8.5%) |
| Ezetimibe 10 mg+ Rosuvastatin 5.0 mg | 0/72 (0%) | 0/72 (0%) | 7/72 (9.7%) |
| Event | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| Bacterial prostatitisInfections and infestations | 0/35 | 0/72 | 1/71 | 0/71 | 0/72 |
| Event | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/35 | 8/72 | 11/71 | 6/71 | 7/72 |
| Age, Continuous(Years) | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 56.0 ± 8.9 | 55.7 ± 10.6 | 58.9 ± 9.0 | 56.0 ± 10.3 | 58.2 ± 10.6 | 57.0 ± 10.1 |
| Sex: Female, Male(Participants) | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg | Total |
|---|---|---|---|---|---|---|
| Female | 16 | 36 | 40 | 37 | 37 | 166 |
| Male | 19 | 36 | 31 | 34 | 35 | 155 |
| Race (NIH/OMB)(Participants) | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 35 | 72 | 71 | 71 | 72 | 321 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ezetimibe 10 mg | Rosuvastatin 2.5 mg | Rosuvastatin 5.0 mg | Ezetimibe 10 mg+ Rosuvastatin 2.5 mg | Ezetimibe 10 mg+ Rosuvastatin 5.0 mg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 35 | 72 | 71 | 71 | 72 | 321 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Jan 2017, 7 months.
Results were first posted in Mar 2018, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 7 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ezetimibe · Rosuvastatin